NVO
Novo Nordisk A/S
38.20$
-0.2%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 69.8% | 14.5% | 21.9% | 74.2% | 61.5% | 14.4% | 31.5% | 53.1% | 61.5% | 9.6% | 24.9% | 70.3% | 40.4% | |
| 4.3% | 4.5% | 4.5% | 13.0% | 3.0% | 6.1% | 4.9% | 6.3% | 10.3% | 7.0% | 3.7% | 13.1% | 8.2% | |
| -5.6% | 3.3% | – | – | – | – | – | – | – | – | – | – | – | |
| 7.3% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 19.9% | -14.7% | -14.7% | 14.5% | -15.8% | 15.9% | -21.0% | 6.2% | -6.6% | 25.7% | -34.3% | 17.0% | -1.4% | |
| 18.1% | 25.0% | 13.8% | 19.5% | 17.5% | 19.3% | 18.7% | 21.2% | 20.6% | 55.4% | 12.4% | 16.3% | 25.5% | |
| -49.7% | -22.3% | 6.1% | -30.5% | -29.3% | -106.5% | -8.5% | -18.5% | -20.6% | -54.1% | -12.1% | -16.3% | -25.1% | |
| 22.9% | 0.0% | 43.7% | 0.0% | 21.9% | 51.5% | 45.2% | 0.2% | 22.2% | 0.3% | 36.5% | 0.0% | 15.9% | |
| -10.5% | -14.8% | -4.3% | -10.9% | -3.4% | -8.7% | -1.8% | -0.1% | -0.1% | 0.0% | -2.5% | -4.5% | -1.8% | |
| -0.4% | – | – | – | -0.6% | 51.7% | 19.6% | -25.5% | -0.6% | 37.2% | 15.2% | -9.4% | 11.1% | |
| -33.8% | -15.4% | -40.4% | 24.5% | -25.8% | 43.0% | 7.0% | -60.2% | -22.8% | 37.2% | -18.0% | -24.4% | -7.3% | |
| 14.1% | -23.5% | -12.3% | 68.3% | 5.9% | -48.3% | 29.8% | -26.7% | 18.2% | -7.1% | -5.5% | 29.8% | 7.9% | |
| 51.7% | -10.5% | 8.1% | 54.8% | 44.0% | -5.0% | 12.8% | 31.9% | 40.9% | -45.8% | 12.4% | 54.0% | 14.8% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.